Fluvoxamine, which is sold as Luvox, is a selective serotonin reuptake inhibitor, or SSRI, typically prescribed for obsessive-compulsive disorder. The drug’s biochemistry implied it might be able to regulate cellular responses to stress and infection. “I immediately dove into the biochemistry,” he says.
TREATMENT BRAIN FOG COVID TRIAL
It wasn’t just the trial results that intrigued Seftel, however. By comparison, six of 72 patients, or 8.3 percent, who took placebo tablets worsened and needed hospitalization, researchers reported in November in the Journal of the American Medical Association. Kirsch shared results from a fund-supported randomized trial in which none of 80 newly diagnosed COVID-19 patients assigned to a two-week course of fluvoxamine became seriously ill. Earlier that month, Seftel had heard about fluvoxamine during a presentation by tech entrepreneur Steve Kirsch, whose COVID-19 Early Treatment Fund supports research on existing drugs that could be repurposed to treat coronavirus infections. Racetrack physician David Seftel and David Boulware, an infectious disease physician-scientist at the University of Minnesota Medical School in Minneapolis, led the real-world test of fluvoxamine after hundreds of workers became infected with the virus around Thanksgiving. Sign up for e-mail updates on the latest coronavirus news and research Food and Drug Administration, could be considered for patients at high risk of suffering severe COVID-19 symptoms. However, some experts say that the new findings, along with cell, animal and human observational data, suggest that a two-week course of fluvoxamine, which costs about $10 and is already approved by the U.S.
TREATMENT BRAIN FOG COVID VERIFICATION
The data need verification from ongoing larger clinical trials. Two got so sick they were put on a ventilator to assist with breathing, and one died, researchers report February 1 in Open Forum Infectious Diseases. In comparison, 12.5 percent of those who turned down the drug wound up hospitalized. Of those who opted to take fluvoxamine, none got sicker, and within two weeks, their symptoms cleared. The results come from real-world use of the drug to treat workers at the Golden Gate Fields horse racing track in Berkeley, Calif. The antidepressant fluvoxamine could prevent people from getting seriously ill with COVID-19, curbing hospitalizations, new data show.
0 kommentar(er)
